This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 300% and 6.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -182.98% and 71.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
ObsEva SA (OBSV) delivered earnings and revenue surprises of 7.14% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Twist Bioscience (TWST) delivered earnings and revenue surprises of 28.91% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of -3.23% and 13.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Alpine Immune Sciences, Inc. (ALPN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -320% and 59.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 20% and 7.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics (ANIK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of -20.83% and 10.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 33.72% and 10.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 10.10% and 3.04%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and 7.92%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Patterson Cos. (PDCO) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of -15.79% and 2.50%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals (KALA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of 13.64% and 18.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?